BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors
Shots:
- The CHMP has granted positive opinion to repotrectinib for treating ROS1+ advanced NSCLC in adults and NTRK+ advanced solid tumors in patients (≥12yrs.), with the EC’s decision anticipated in Jan 2025
- Opinion was based on P-I/II (TRIDENT-1 & CARE) trials, with TRIDENT-1 assessing repotrectinib in advanced solid tumors (NSCLC and tumors with ROS1 & NTRK fusions), while CARE focuses on pediatric & young adults with ALK, ROS1, or NTRK gene alterations
- Trials showed meaningful response rates in the patients along with strong durable responses and intracranial activity; safety profile was manageable with standard treatments. Study continues to assess long-term outcomes and additional EPs
Related News:- BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
